Drugs in Dev. Neurology
Phase I
Finland 
Orion Terminates ODM-111 Program Due To Narrow Therapeutic Window Challenges
Details : ODM-111 is NaV. 1.8 blocker was being evaluated in the early-stage clinical trial studies with the patients for the treatment of acute and chronic pain.
Product Name : ODM-111
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2024
First Patients Dosed in Final Cohort of HER-096 Parkinson’s Phase 1b Trial
Details : HER-096 is a CDNF mimetic that has the potential to protect against the neuronal degeneration and cell death that cause the symptoms of Parkinson’s disease.
Product Name : HER-096
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 13, 2025
Nanoform's Final Clinical Results Confirm Value Proposition to the Pharma Industry
Details : The primary objective of the study was to determine the PK and relative bioavailability of piroxicam following oral administration of single 20 mg nanoformed piroxicam IR tablets and reference product Felden 20mg tablets (Pfizer) in healthy subjects in t...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2021
Reset All
